?-Adducin polymorphism associated with increased risk of adverse cardiovascular outcomes: Results from GENEtic Substudy of the INternational VErapamil SR-trandolapril STudy (INVEST-GENES) - 09/08/11
for the INVEST Investigators
Résumé |
Background |
The α-adducin (ADD1) Gly460Trp polymorphism has been associated with hypertension and response to diuretic therapy, but controversy exists.
Methods |
The present study was conducted to prospectively investigate the relationship among the ADD1 Gly460Trp polymorphism, diuretic use, and adverse cardiovascular outcomes among 5,979 patients with hypertensive coronary artery disease, who participated in the INVEST and provided genomic DNA. The primary outcome was defined as the first occurrence of nonfatal stroke, nonfatal myocardial infarction, or all-cause death. Secondary outcomes were the components of the primary outcome. Ancestry informative markers were used to control for population stratification.
Results |
In blacks, ADD1 variant carriers were at higher risk for a primary outcome event than wild-type homozygotes (adjusted hazard ratio 2.62, 95% CI 1.23-5.58, P = .012), with a similar trend in whites and Hispanics, albeit a smaller magnitude of effect (adjusted hazard ratio 1.43, 0.86-2.39 in Hispanics; 1.24, 0.90-1.71 in whites). Secondary outcome analysis showed that the all-cause death was driving the differences in primary outcomes by genotype. There was no interaction between the ADD1 polymorphism and diuretic use for either primary outcome or secondary outcomes.
Conclusions |
In hypertensive patients with coronary artery disease, black ADD1 variant carriers showed a 2.6-fold excess risk for a primary outcome event and an 8-fold increase risk of death. White and Hispanic ADD1 variant carriers showed an increased but nonsignificant excess risk. However, the effect of diuretic use on risk of cardiovascular outcomes did not vary by ADD1 carrier status.
Le texte complet de cet article est disponible en PDF.Plan
Vol 156 - N° 2
P. 397-404 - août 2008 Retour au numéro
Article précédent
- Long-term outcome of primary angioplasty compared with fibrinolysis across age groups: A Danish Multicenter Randomized Study on Fibrinolytic Therapy Versus Acute Coronary Angioplasty in Acute Myocardial Infarction (DANAMI-2) substudy
- Emil Loldrup Fosbøl, Jens Jakob Thune, Henning Kelbæk, Henning Rud Andersen, Kari Saunamäki, Torsten Toftegaard Nielsen, Leif Spange Mortensen, Lars Køber, for the DANAMI-2 investigators
- Metabolic syndrome, endothelial dysfunction, and risk of cardiovascular events: The Northern Manhattan Study (NOMAS)
- Takeki Suzuki, Kumiko Hirata, Mitchell S.V. Elkind, Zhezhen Jin, Tanja Rundek, Yumiko Miyake, Bernadette Boden-Albala, Marco R. Di Tullio, Ralph Sacco, Shunichi Homma
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?